Zydus to begin Phase I trials of its inflammation drug, ZYIL1

Phase I trial will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in healthy human volunteers. Zydus has secured a Strong IP portfolio with multiple patents filed in all major countries

0
56
New Delhi: Zydus, a leading discovery company based in Ahmedabad has announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.
NLRP3 inflammasomes are involved in the inflammation process by production and release of pro-inflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, Gastro-intestinal diseases (inflammatory bowel disease), renal diseases and CNS diseases.
Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, “We will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this Phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need.”